Skip to main content
SpringerLink
Log in

Subchronic exposure to high-dose ACE-inhibitor moexipril induces catalase activity in rat liver

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

The long-term clinical effects of ACE-inhibitors have similarities with those of both fibrates and glitazones, activators of peroxisome proliferator activator receptor (PPAR) alpha and gamma, respectively. The antioxidant enzyme catalase, a heme protein that degrades hydrogen peroxide, is found at high concentrations in peroxisomes. Catalase activity is one of the recognized surrogate markers indicative of PPAR activation in the rat liver. The purpose of the study was to establish the effect of moexipril on catalase activity and to compare it with the effect of both saline controls and that of the known PPAR agonist clofibrate (positive control). Three groups of seven rats were used. All substances were applied i.p. daily for 5 days, followed by a 2-day break. The cycle was repeated eight times. After the final cycle (day 56) the animals were sacrificed and liver tissue collected. The number of catalase positive cells in both moexipril group (95% CI 57–61) and clofibrate group (95% CI 72–80) is higher than in controls (95% CI 3–16) (p ≤ 0.01). The number of catalase positive cells in the clofibrate group is higher than in the moexipril group (p ≤ 0.01). High-dose subchronic exposure to the ACE-inhibitor moexipril induces catalase activity in the rat liver to an extent comparable to fibrates. We suggest that some of the long-term advantages of ACE inhibitor use – beyond mere BP lowering – might be due to a PPAR mediated effect. (Mol Cell Biochem xxx: 159–163, 2005)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gerstein HC: Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 18: 82–85, 2002

    Article  CAS  Google Scholar 

  2. Zanella MT, Kohlmann O Jr, Ribeiro AB: Treatment of obesity hypertension and diabetes syndrome. Hypertension 38: 705–708, 2001

    PubMed  CAS  Google Scholar 

  3. McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 91: 30–37, 2003

    Article  CAS  Google Scholar 

  4. Mehendale HM: PPAR-alpha: A key to the mechanism of hepatoprotection by clofibrate. Toxicol Sci 57: 187–190, 2000

    Article  PubMed  CAS  Google Scholar 

  5. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, Sawada H: Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278: 704–711, 2000

    Article  PubMed  CAS  Google Scholar 

  6. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 351: 1106–1118, 2004

    Article  PubMed  Google Scholar 

  7. Wilcke M, Alexson SE: Differential induction of peroxisomal populations in subcellular fractions of rat liver. Biochim Biophys Acta 1544: 358–369, 2001

    PubMed  CAS  Google Scholar 

  8. Girnun GD, Domann FE, Moore SA, Robbins ME: Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol 16: 2793–2801, 2002

    Article  PubMed  CAS  Google Scholar 

  9. Akbiyik F, Cinar K, Demirpence E, Ozsullu T, Tunca R, Haziroglu R, Yurdaydin C, Uzunalimoglu O, Bozkaya H: Ligand-induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver. Eur J Clin Invest 34: 429–435, 2004

    Article  PubMed  CAS  Google Scholar 

  10. Akbiyik F, Ray D, Bozkaya H, Demirpence E: Ligand- and species-dependent activation of PPARalpha. Cell Physiol Biochem 14: 269–276, 2004

    Article  PubMed  CAS  Google Scholar 

  11. Zamboni L, de Martino C: Buffered picric acid-formaldehyde: A new rapid fixation for electron microscopy. J Cell Biol 35: 148A, 1967

  12. Perneger TV: What's wrong with Bonferroni adjustments? BMJ 316: 1236–1238, 1998

    Google Scholar 

  13. Smith CG, Vane JR: The Discovery of Captopril. FASEB J 17: 788–789, 2003

    Article  PubMed  CAS  Google Scholar 

  14. Cushman DW, Ondetti MA: History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 17: 589–592, 1991

    PubMed  CAS  Google Scholar 

  15. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: A concise review. J Clin Pharmacol 44: 827–836, 2004

    PubMed  CAS  Google Scholar 

  16. Cawello W, Boekens H, Waitzinger J, Miller U: Moexipril shows a long duration of action related to an extended pharmacokinetic half life and prolonged ACE inhibition. Internat J Clin Pharmacol Ther 40: 9–17, 2002

    CAS  Google Scholar 

  17. Brogden RN, Wiseman LR: Moexipril. A review of its use in the management of essential hypertension. Drugs 55: 845–860, 1998

    PubMed  CAS  Google Scholar 

  18. Thorp JM, Waring WS: Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature 194: 948–949, 1962

    PubMed  CAS  Google Scholar 

  19. Crouthamel WG, Cenedella RJ: Clofibrate pharmacokinetics: Effect of elevation of plasma-free fatty acids. Pharmacology 13: 465–473, 1975

    Article  PubMed  CAS  Google Scholar 

  20. Sridhar GR: Peroxisome proliferator-activated receptors as molecular targets for drug therapy. J Assoc Physicians India 51: 49–52, 2003

    PubMed  CAS  Google Scholar 

  21. Roglans N, Bellido A, Rodriguez C, Cabrero A, Novell F, Ros E, Zambon D, Laguna JC: Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver. Clin Pharmacol Ther 72: 692–701, 2002

    Article  PubMed  CAS  Google Scholar 

  22. Ammerschlaeger M, Beigel J, Klein KU, Mueller SO: Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes. Toxicol Sci 78: 229–240, 2004

    Article  PubMed  CAS  Google Scholar 

  23. Tordjman K, Standley KN, Bernal-Mizrachi C, Leone TC, Coleman T, Kelly DP, Semenkovich CF: PPARalpha suppresses insulin secretion and induces UCP2 in insulinoma cells. Lipid Res 43: 936–943, 2002

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Therapeutics, UAE University, Faculty of Medicine and Health Sciences, Al Ain, UAE

    M. Y. Hasan, S. M. Nurulain & G. A. Petroianu

  2. Department of Anatomy, UAE University, Faculty of Medicine and Health Sciences, Al Ain, UAE

    E. Adeghate & A. S. Ponery

  3. Department of Pharmacology and Therapeutics, United Arab Emirates University, P.O. Box 17666, Al Ain, United Arab Emirates

    G. A. Petroianu

Authors
  1. E. Adeghate
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Y. Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. S. Ponery
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. M. Nurulain
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. A. Petroianu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. A. Petroianu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adeghate, E., Hasan, M.Y., Ponery, A.S. et al. Subchronic exposure to high-dose ACE-inhibitor moexipril induces catalase activity in rat liver. Mol Cell Biochem 280, 159–163 (2005). https://doi.org/10.1007/s11010-005-8843-6

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-005-8843-6

Keyword

Search

Navigation